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AU-rich element mRNA-binding proteins (AUBPs) are key regulators of development, but how they are controlled and what functional roles they play depends on cellular context. Here, we show that Brf1 (zfp36l1), an AUBP from the Zfp36 protein family, operates downstream of FGF/Erk MAP kinase signaling to regulate pluripotency and cell fate decision making in mouse embryonic stem cells (mESCs). FGF/Erk MAP kinase signaling up-regulates Brf1, which disrupts the expression of core pluripotency-associated genes and attenuates mESC self-renewal without inducing differentiation. These regulatory effects are mediated by rapid and direct destabilization of Brf1 targets, such as Nanog mRNA. Enhancing Brf1 expression does not compromise mESC pluripotency but does preferentially regulate mesendoderm commitment during differentiation, accelerating the expression of primitive streak markers. Together, these studies demonstrate that FGF signals use targeted mRNA degradation by Brf1 to enable rapid posttranscriptional control of gene expression in mESCs. stem cell biology | AU-rich element RNA-binding proteins | developmental mechanisms | developmental signaling pathways | gene regulation dynamics A U-rich element mRNA-binding proteins (AUBPs) represent an important class of regulators required for the proper development of embryonic and adult tissues in the mouse (1), but whether they have developmentally important roles in mouse embryonic stem cells (mESCs) remains unclear. A recent proteomic survey identified more than 500 mRNA-binding proteins in mESCs, several of which are AUBPs (2) . Independent of the micro-RNA pathway, AUBPs are known regulators of splicing, mRNA stability, translational efficiency, and RNA transport (3), and could provide an additional layer of developmental regulation that complements other pluripotency and self-renewal mechanisms. AUBPs are essential in many developmental systems, such as during hematopoiesis, neurogenesis, germ cell commitment, and placental morphogenesis (4) (5) (6) . Their absence or misregulation can be lethal and often promotes disease progression (7) (8) (9) . Despite growing interest in the many functions of AUBPs, their regulation and function in mESCs remains poorly understood.
The expression and activity of AUBPs is known to be regulated by growth factor signaling in many cellular contexts (10, 11) . In mESCs, the FGF/Erk MAP kinase signaling pathway is a central regulator of self-renewal, pluripotency, and differentiation (12, 13) . Although much is known about the developmental effects of FGF/Erk MAP kinase signaling inhibition or activation (14, 15) , the regulatory mechanisms used downstream of Erk1/2 often remain unclear. Various transcriptional, posttranscriptional, and posttranslational mechanisms are engaged to regulate target genes (16) . As part of this signaling cascade, AUBPs could mediate rapid signaling-dependent responses, but this potential role has not been investigated.
Here, we show that the expression of Brf1 (zfp36l1) is regulated by FGF/Erk MAP kinase signaling in both pluripotent and differentiating mESCs. Brf1 is a member of the Zfp36 AUBP family that plays critical roles throughout mouse development. Without Brf1, embryos die in utero at approximately embryonic day 10.5 (E10.5) as a result of allantoic, placental, and neural tube defects (9) , and its absence in adults promotes leukemia (17) . In mESCs, Brf1 binds AU-rich sequences in many pluripotency-associated mRNAs, including Nanog, to regulate their localization and abundance. This regulation broadly perturbs the core transcription factor network without inducing differentiation, but compromises the capacity to self-renew. In differentiationstimulating conditions, Brf1 enhances the expression of primitive streak markers, indicating an accelerated commitment to mesendoderm. Together, these data identify targeted mRNA degradation by Brf1 as a mechanism through which the biology of mESCs is regulated and controlled by FGF/Erk MAP kinase signals.
Results
Erk MAP Kinase Signaling Regulates the Expression of Zfp36 AUBPs.
AUBP expression in mESCs has been documented by several groups (2, 9, 18) . The known sensitivity of AUBPs to growth factors suggested that these proteins could be regulated by FGF/ Erk MAP kinase signaling (11, 19) . To explore this potential regulatory connection, we first profiled the transcriptome of E14 mESCs using high-throughput sequencing to determine which AUBPs are actively expressed ( Fig. 1A and Dataset S1). We identified several classes of AUBPs, including (i) members of the Significance Intercellular signaling pathways strongly regulate gene expression in uncommitted precursor stem cells, but the mechanisms through which these signaling pathways regulate gene targets often remain unclear. We address this question in mouse embryonic stem cells (mESCs) and highlight the importance of AU-rich element mRNA-binding proteins as regulatory intermediates of intercellular signaling. We show that the FGF/Erk MAP kinase signaling pathway strongly influences the expression of Brf1, a member of the Zfp36 protein family that is known to bind and destabilize its mRNA targets. Brf1 physically binds many pluripotency and differentiation-associated mRNAs. Moderate changes in its expression compromise selfrenewal capacity and bias fate commitment, thus providing a posttranscriptional link between intercellular signaling activity and gene expression in mESCs.
Zfp36 protein family [TTP (zfp36), Brf1 (zfp36l1), and Brf2 (zfp36l2)], which are known to play critical roles during hematopoiesis by destabilizing Cytokine and Notch-Delta signalingassociated mRNAs; (ii) members of the Hu protein family [HuR (elavl1), HuB (elavl2)], which stabilize their mRNA targets and are known to actively regulate germ cell development; and (iii) Auf1 (hnrnpd), which can stabilize or destabilize mRNA and modulate inflammation in the adult mouse (20) .
To determine whether any of the detected AUBPs was regulated by FGF/Erk MAP kinase signaling, we measured changes in their expression in response to pharmacological inhibitors of MEK1/2. We discovered that TTP and Brf1 responded strongly to MEK1/2 inhibition, with mRNA levels down-regulated greater than twofold after 5 and 10 h ( Fig. 1B) . Brf2, Auf1, and KHSRP mRNA levels were also slightly down-regulated. Interestingly, three out of five of these responding genes are members of the Zfp36 protein family ( Fig. 1B , red bracket).
Changes in Erk MAP Kinase Signaling Lead to Transient and Sustained
Zfp36 Responses. We explored the regulatory connection between Zfp36 AUBPs and FGF/Erk MAP kinase signaling further by measuring how TTP, Brf1, and Brf2 responded to short and long periods of MEK1/2 inhibition ( Fig. 2A ). Incubation with MEK1/2 inhibitor resulted in a rapid reduction in TTP, Brf1, and Brf2 mRNA level as gauged by reverse transcription-quantitative PCR (RT-qPCR) ( Fig. 2B ). Brf1, Brf2, and, to a lesser extent, TTP mRNA level changes were significant within 1 h of inhibitor treatment ( Fig. S1A ) and continued to decrease after 7.5 h of inhibition ( Fig. 2B ). However, after 10 h, TTP and Brf2 mRNA expression recovered, whereas Brf1 expression remained suppressed ( Fig. 2B ). Because the pharmacological inhibitor provides continuous suppression of Erk MAP kinase signaling ( Fig. 2 and Fig.  S1B ), these data indicate that TTP and Brf2 mRNA respond only transiently (t < 10 h) to changes in Erk MAP kinase signaling, whereas Brf1 mRNA maintains a sustained response to the level of Erk MAP kinase signaling. Protein level changes were also rapid, with a 30% reduction in TTP and a 50% reduction in Brf1 within 1.5 h of inhibitor treatment ( Fig. 2 and Fig. S1C ). However, whereas Brf1 protein levels continued to fall for the remainder of the time course, reaching ∼10-fold less protein by 30 h, TTP protein levels recovered and increased above DMSO-treated controls (Fig. 2C ). These data indicate that the regulation of TTP protein becomes distinct from the regulation of TTP mRNA at later times (compare Fig. 2 B and C). We note that, in other cellular contexts, direct phosphorylation of TTP protein by Erk1/2 has been shown to reduce its stability (10) . Furthermore, Zfp36 AUBPs also contain AU-rich sequences in their own mRNAs, which enable direct autoregulation and cross-regulation ( Fig. 2 and Fig.  S1D ). These mechanisms could explain why TTP protein and mRNA levels respond differently after prolonged MEK1/2 inhibition. In contrast, Brf2 protein levels were much less affected, dropping slightly at 10 h, and then recovering at later time points. Thus, at both the mRNA and protein levels, Brf2 responds more weakly to these perturbations (compare Fig. 2 B and C). These results indicate that AUBP levels respond to changes in Erk MAP kinase signaling with different kinetics. To further validate these findings, we checked whether upregulating FGF signaling could produce opposite results to inhibition ( Fig. 2A ). We added FGF4/heparin to fgf4 −/− R1 mESCs (strain FD6), to activate Erk MAP kinase signaling ( Fig. 2D ) (21) . TTP, Brf1, and Brf2 mRNA levels increased within 5 h of ligand addition, with similar changes at the protein level ( Fig. 2 E and F). These changes occurred specifically within the cytoplasmic compartment, consistent with a role for these AUBPs in regulating targeted degradation of mature mRNAs (Fig. 2F ). Together, these results indicate Zfp36 protein expression responds rapidly to both increases and decreases in FGF/Erk MAP kinase signaling activity, leading to both transient (TTP, Brf2) and sustained (Brf1) regulatory responses.
Enhancing Brf1 Compromises mESC Self-Renewal. Among the Zfp36 AUBPs, FGF/Erk MAP kinase signaling most strongly regulated the expression of Brf1 in pluripotent conditions (Fig. 2 ). During differentiation, Brf1 regulation was also dynamic and continued to be regulated by FGF/Erk MAP kinase signaling (Fig. 3A) . The approximately twofold reduction in Brf1 expression over 4 d of LIF withdrawal (Fig. 3A ) tracked concomitant changes in FGF4 expression ( Fig. 3B ), and the down-regulation of the Erk MAP kinase target genes Spred2 and Spry2 (Fig. 3B ).
To determine the functional effect of Brf1 on pluripotent and differentiating cells, we perturbed Brf1 expression using siRNAs, which produced an approximately fourfold decrease in Brf1 protein relative to wild type. We also created stable transgenemediated overexpression cell lines, which increased Brf1 protein levels approximately fourfold above wild-type levels (Fig. 3C ). For transgene expression in mESCs, clones expressing H2B-YFP (Brf1 1× ) or Brf1-T2A-H2B-YFP (Brf1 4× ) were derived for these studies. Of these, one control Brf1 1× clone that expressed wildtype levels of Brf1 protein, and one Brf1 4× clone expressing approximately fourfold more Brf1 protein, was chosen for further analysis.
To quantify changes in mESC self-renewal brought about by Brf1 overexpression, we cocultured YFP(+) Brf1 4× clones with wild-type YFP(−) E14 mESCs. In this assay, any change in selfrenewal ability manifests as changes in relative proliferation rate, and hence, a change in the YFP(+)/YFP(−) ratio (22) . Compared with Brf1 1× , cocultures with Brf1 4× exhibited a significant proliferation defect, with the YFP(+)/YFP(−) ratio reduced by ∼20% every 48 h (Fig. 3D ). In these cells, the expression of several core pluripotency genes is altered ( Fig. 3E ). However, most remain pluripotent in conditions with LIF plus serum (see below). Removing LIF rapidly initiates differentiation, and during the first 48 h, Brf1 siRNA knockdown in Brf1 1× or Brf1 overexpression in Brf1 4× produced only modest effects on the rate at which some markers of pluripotency were down-regulated ( Fig. 3F ).
Enhancing Brf1 Expression Accelerates Mesendoderm Differentiation.
In contrast to the mild effect of Brf1 expression on the downregulation of pluripotency factors (Fig. 3F ), the up-regulation of differentiation markers is strongly affected by Brf1 (Fig. 4A) . After 3 d of LIF withdrawal, we observed a striking bias in gene expression when comparing Brf1 4× to Brf1 1× cultures. LIF withdrawal generally promotes mesoderm differentiation (23) . Indeed, Brachyury (T) was up-regulated in differentiating Brf1 1× and Brf1 4× cultures. However, Brachyury expression was 100-fold greater in the Brf1 4× cell line (Fig. 4B ). Transfecting Brf1 1× cultures with Brf1 siRNAs produced the opposite effect, downregulating Brachyury expression approximately fourfold relative to untreated controls (Fig. 4B ). Furthermore, siRNAs against Brf1 could attenuate the up-regulation of Brachyury in Brf1 4× , indicating that this regulation resulted specifically from Brf1 overexpression. In agreement with these results, flow cytometry profiling indicated that a larger fraction of Brf1 4× cells expressed Brachyury protein by 84 h compared with Brf1 1× (Fig. 4D) . These findings were further supported by the up-regulation of mesendodermal markers Goosecoid (Gsc), Mixl1, and Wnt3A (Fig. 4B) , indicating that Brf1 accelerated commitment to mesendodermal fates. Ectoderm markers (Nodal, Fgf5, and Gbx) were not affected, whereas extraembryonic and definitive endoderm markers (Gata6, Hnf4a, and FoxA2) showed weaker basal expression levels that responded differentially to Brf1 (Fig. 4B ).
Brf1 expression did not influence neural differentiation. Because serum inhibits neural differentiation (24), we cultured cells in N2B27 serum-free media without LIF and BMP4. After 3 d in this media, most markers of differentiation appeared to be unaffected by Brf1 (Fig. 4C ). For example, Sox1 mRNA and protein were readily detected, but its expression levels were similar in Brf1 1× and Brf1 4× cultures ( Fig. 4 C and D) . Interestingly, even in N2B27, the basal expression of Brachyury was up-regulated in a Brf1-dependent manner. Thus, Brf1 appears to mainly affect mesendodermal differentiation pathways.
Brf1 Binds Pluripotency-Associated mRNAs. To better understand the mechanistic basis for these developmental effects, we profiled possible Brf1 mRNA targets in mESCs. To determine which actively expressed genes are bound by Brf1, we adapted a previously developed RNA immunoprecipitation sequencingbased (RIPseq) assay that could selectively enrich target mRNAs using an affinity-purified polyclonal antibody against Brf1 (Fig.  5A ; Materials and Methods) (25) . In parallel, we performed a negative control using a nonspecific rabbit IgG. RNA from samples and controls were then processed and analyzed using highthroughput sequencing.
To provide a quantitative measure of antibody-mediated enrichment, we computed a statistic, denoted E RIP for each actively expressed transcript (Materials and Methods). E RIP represents the amount of mRNA coprecipitated with Brf1 protein over nonspecific background levels (Materials and Methods). Genes with high E RIP values were more likely to have AU-rich elements (AREs) in their 3′-UTR (Fig. 5B ). For example, considering the transcripts most enriched by Brf1 immunoprecipitation (positive outliers, E RIP > 1.226, 418 genes), 25.1% contained the minimal full consensus ARE and 60.0% contained the minimal partial consensus ARE. These percentages represent a threefold to fourfold increase in ARE abundance relative to their frequency among all protein coding genes (Table S1 and Datasets S2-S4). Moreover, several of the most highly enriched target genes were previously characterized as direct targets of Zfp36 proteins (e.g., Ier3, Mllt11, and Pim3), including Zfp36 proteins themselves (26, 27) . Interestingly, based on our definition of the minimal ARE element, many highly enriched target genes do not contain consensus AREs. However, the existence of noncanonical (although still poorly characterized) AU-rich sequences has been documented and could explain the enrichment of these mRNAs (28) . Thus, the RIPseq assay can selectively enrich for mRNAs containing AREs.
Several pluripotency-associated factors were detected in the Brf1-RIP fraction, potentially explaining the developmental effects of Brf1 overexpression. For example, the core pluripotency regulators Nanog (E RIP = 0.58) and Klf2 (E RIP = 7.15) were both within the top quartile of enriched targets. Nanog broadly inhibits mESC differentiation, and its expression is reduced as cells lose pluripotency and commit to extraembryonic and somatic cell lineages in culture (29, 30) . Klf2, along with Klf4 and Klf5, inhibits mesendoderm differentiation. Knockdown of Klf factors upregulates primitive streak markers, as well as Cdx2, a gene expressed in trophectoderm and extraembryonic mesoderm (31) . Also consistent with a role for Brf1 in promoting mesendoderm, the pluripotency factors Kdm4c (E RIP = 0.63) and Zfp143 (E RIP = 0.99) were enriched in the RIPseq assay. Knockdown of the lysine methyl-transferase Kdm4c is known to up-regulate mesendoderm and extraembryonic mesoderm markers (32) . Zfp143 coordinates with Oct4 to transcriptionally activate Nanog. siRNA knockdown of Zfp143 rapidly initiates differentiation and promotes the expression of Fgf5, Cdx2, and Cdh3, which are expressed in trophectoderm and cells that commit to extraembryonic mesoderm (33) . Understanding the regulation of these mRNAs may provide additional mechanistic insights into the Brf1-dependent control of gene expression in mESCs.
Brf1 Binds Nanog mRNA in Vitro. To corroborate these RIPseq results, we assayed for direct binding of Brf1 to an enriched mRNA, in this case, Nanog (Fig. 6A) . Previous work has shown that Nanog is strongly regulated by FGF/Erk MAP kinase signaling (34) , and these effects are mediated, in part, by direct regulation of the Nanog promoter (35) . Posttranscriptional regulation by Brf1 would provide an alternative mechanism to repress Nanog expression.
We conducted a protein pull-down assay using RNA as bait ( Fig. 6B, Left) . Wild-type RNA and variants with ARE sequence mutations were expressed in vitro and hybridized at their 3′ ends to DNA oligonucleotides coupled to magnetic microbeads. These RNA-microbead conjugates were then incubated with crude cytoplasmic protein extracts, and all proteins capable of binding hybridized RNAs were magnetically isolated and purified for further analysis.
We used the 3′-UTR sequence of IL-2 as a positive control, because it contains clusters of ARE sequences that are bound and regulated by Zfp36 AUBPs (Fig. S2A) (36) . Western blots showed that Brf1 could be purified from mESC lysates using a conjugated wild-type IL-2 sequence, but not using a mutant IL-2 lacking known AREs (Fig. 6B ). Two Brf1 bands of different sizes were detected, possibly indicating the purification of different posttranslationally modified forms of Brf1 (Fig. 6B) .
We next repeated the assay using Nanog mRNA as bait. The 3′-UTR of Nanog mRNA is ∼1 kb and contains three potential ARE elements: one full consensus (site 1 in Fig. 6A ) and two partial nonconsensus sequences (sites 2 and 3 in Fig. 6A ). Western blotting of these protein pull downs indicated that Brf1 bound to wild-type Nanog mRNA (Fig. 6B ). Mutating the fullconsensus ARE (site 1) significantly reduced Brf1 binding. Removing the remaining two partial nonconsensus AREs (sites 2 and 3) did not appear to further reduce the Brf1 signal. In contrast, the presence or absence of AREs did not affect the binding of other RNA-binding proteins (RBPs). For example, addition of an androgen receptor 3′-UTR sequence, which contains a poly(C) RNA-binding protein 1 (PCBP1) site, to Nanog mRNA permitted isolation of PCBP1 protein (Fig. S2B) . This binding was not affected by the presence or absence of Nanog's AREs. In contrast, a Nanog mRNA containing only a 120-nt poly(A) without a PCBP1 site did not bind PCBP1 protein. Together, these results confirm that Brf1 binds specifically to Nanog mRNA in an ARE-dependent manner.
FGF/Erk MAP Kinase Signaling Regulates Nanog mRNA Half-Life Through its AREs. To understand how Brf1 binding impacts Nanog expression, we measured the Nanog mRNA half-life, with or without AREs, and with or without FGF signaling, in fgf4 −/− mESCs (Fig. 6C ). We determined that the half-life of Nanog mRNA is 2.5 ± 0.4 h (±SEM) without FGF4/heparin and 1.5 ± 0.3 h (±SEM) with Fgf4/heparin (Fig. 6C, Top) . However, removing all 3′-UTR ARE sites [ΔARE (1-3)] protected Nanog from increased degradation by FGF signaling (Fig. 6C, Middle) , indicating that FGF destabilizes Nanog mRNA through its AREs. Additionally, when we analyzed H2B-YFP mRNA as a negative control, we observed no effect of FGF signaling on halflife (Fig. 6C, Bottom) .
Unexpectedly, mutant Nanog mRNA [ΔARE (1-3)] exhibited a shorter half-life than wild type (2 h instead of 2.5 h; Fig. 6C ). In the absence of FGF, we would have expected that the half-life of mutant and wild-type mRNAs to be the same. However, it is possible that Nanog's AREs are subject to regulation by other protein factors that have different effects. For example, AREs could associate with stabilizing AUBPs, such as HuR, whose activity is independent of FGF/Erk MAP kinase signaling in mESCs (Fig. 1C ). Primary sequence changes may have also affected mRNA stability independent of any particular AUBP. Despite this difference, the above data clearly show that Nanog's AREs are necessary for any posttranscriptional regulation by FGF.
To show that FGF regulates Nanog through Brf1, we conducted an epistasis test in fgf4 −/− R1 mESCs. We transfected mock or Brf1 siRNAs, and measured changes in Brf1 and Nanog mRNA level both in the presence and absence of FGF4/heparin. Relative to siRNA control (Fig. 6D, first column) , Brf1 siRNAs caused a slight (∼10%) down-regulation of Brf1 and a corresponding increase in Nanog mRNA levels (Fig. 6D , second column). These data indicate that Brf1 is expressed, albeit at a lower level, even when FGF signaling is absent (Fig. S2C) and that alternative pathways support its basal expression. We confirmed that FGF signaling remains the dominant regulator of Erk in mESCs ( Fig. 2D ) and that Erk MAP kinase signaling is the main driver of Brf1 expression ( Fig. S2C) .
Addition of FGF4/heparin ligand increased Brf1 and decreased Nanog by greater than twofold within 5 h (Fig. 6D, third  column) . In agreement with its role as a regulatory intermediate, the presence of Brf1 siRNAs reduced this regulation, yielding a smaller up-regulation of Brf1 and a smaller down-regulation of Nanog (Fig. 6D ). We note that the inability of Brf1 siRNAs to fully block the down-regulation of Nanog can be partly explained by its limited knockdown efficiency (∼75%) ( Fig. 3C ) but could also reflect Brf1-independent regulatory mechanisms.
FGF/Erk MAP kinase signaling thus regulates the dynamic expression of Zfp36 AUBPs in mESCs, which in turn affect the stability of key mRNA targets. In particular, we show that Brf1 (zfp36l1) has the capacity to broadly impact the regulation of core pluripotency-associated transcription factors, down-regulate self-renewal, and promote lineage-specific commitment during differentiation. In this way, Brf1 provides a specific molecular link between FGF/Erk MAP kinase signaling and the regulation of gene expression in mESCs. repression of TNF-α in response to p38/Erk MAP kinase signals during inflammation (37) , and the stabilization of p21 in response to ATR/ATM kinase activation after DNA damage (38) .
Discussion
Here, we demonstrate AUBPs mechanistically connect FGF/Erk MAP kinase signaling to the regulation of pluripotency, self-renewal, and differentiation in mESCs. More specifically, control over Brf1 expression rapidly regulates the expression of key pluripotency-associated genes, reduces the capacity to self-renew, and enhances mesendoderm differentiation upon LIF withdrawal. Why has Brf1 been selected for implementing FGF-dependent cellular responses in mESCs? One possibility is that, owing to its rapid transcriptional response to FGF signaling and its short protein and mRNA half-life (∼1.5 and ∼1 h, respectively), Brf1 is capable of tracking dynamic changes in Erk MAP kinase activity. Brf1 directly affects mRNA abundance and provides stem cell populations with a mechanism to quickly respond to changes in FGF signaling, without necessarily altering underlying transcriptional states. However, the benefit of these dynamical properties to the biology of pluripotent or differentiating mESCs still remains unclear. Brf1 also provides a regulation that is similar to miRNAs, which also provide mRNA-level repression while maintaining flexibility in target selection. Interestingly, Zfp36 AUBPs and miRNAs are known to cooperate in regulating some mRNA targets (39) , indicating a potential point of convergence between these two regulatory mechanisms. Future work will address why this system is particularly well adapted to serve as a regulator in mESCs, and as a mediator of FGF/Erk MAP kinase signaling.
Whether Brf1 plays a similar role in the embryo is unclear. We note that the regulatory effects of Brf1 in cell culture mimic the developmental response to FGF/Erk MAP kinase signaling at different stages of embryonic development. For example, FGF4 signaling promotes extraembryonic endoderm differentiation in the inner cell mass partly by destabilizing the expression of pluripotency genes (40) . Brf1 may participate in this process by repressing Nanog and other pluripotency regulators. At a slightly later developmental stage, and one that is more relevant to mESCs, both FGF4 and FGF8 are required for mesoderm induction (41, 42) . The expression of Brachyury, a regulator of mesoderm morphogenesis, is enhanced by FGF4 and FGF8 signaling through unknown mechanisms (43) . Our results show that Brf1 expression during differentiation in mESCs similarly enhances Brachyury and other primitive streak markers. This regulatory connection could explain why Brf1 knockout mice also exhibit the same gross defects in chorio-allantoic fusion, neural tube closure, and placental organization at midgestation (E11) as FGFR2 knockouts, an indication of shared regulation and function (9, 44) . Although the regulation of FGF/Erk MAP kinase signaling likely differs between the embryonic and cell culture context, these observations implicate Brf1 as an important FGF/Erk MAP kinase-inducible regulator of development in both systems.
Materials and Methods
RT-qPCR Experiments. Total RNA was harvested from samples and controls using Qiazol Reagent (Qiagen) or an RNeasy Mini Kit (Qiagen). RT of iso- lated mRNA into cDNA was accomplished using iScript cDNA Synthesis Kit (Bio-Rad). A single qPCR reaction was composed of 0.5 μL of cDNA, primers or primers with probes, and qPCR reaction mix (diluted to a final volume of 10 μL). For qPCR experiments using TaqMan/hydrolysis probes (5′ dye: fluorescein amidite; 3′ quencher: Zen/Iowa Black FQ), cDNAs were profiled with SsoFast Probes Supermix Reagent (Bio-Rad) using the manufacturerrecommended protocol. In brief, we used a two-step thermocycling protocol (an initial 30-s 95°C melt, followed by 40 cycles of 5-s 95°C melt and 10-s 60°C anneal/extend). For mRNA half-life qPCR experiments using primers only, cDNAs were profiled with SsoFast EvaGreen Supermix Reagent (Bio-Rad) using the manufacturer-recommended protocol. In brief, we used a two-step thermocycling protocol (initial 30-s 95°C melt, followed by 40 cycles of 5-s 95°C melt and 10-s 55°C anneal/extend), terminating with a postamplification melt curve analysis (initialized at 60°C, and increased at 0.5°C increments every 10 s to 95°C). All measurements were made using a Bio-Rad CFX96 Real-Time PCR System (Bio-Rad). See primer and probe characterization (Table S2) .
Cell Lines and Cell Culture. fgf4 −/− mESCs (strain FD6) were a kind gift from Dr. Angie Rizzino (University of Nebraska Medical Center, Omaha, NE).
Cultures were routinely passaged in complete ES culture medium [15% (vol/vol) FBS, 1,000 U/mL LIF, nonessential amino acid (NEAA), sodium pyruvate, and β-mercaptoethanol (βME) in DMEM] in the absence of feeders. Mesoderm differentiation media contained the following: 15% (vol/vol) FBS, NEAA, sodium pyruvate, and βME in DMEM (23); neurectodermal differentiation media contained the following: N2B27 serum free media (45) .
Reagents, Antibodies, Signaling Inhibitors, and siRNAs. Reagents included the following: Qiazol reagent (Qiagen); iScript Kit (Bio-Rad); SsoFast Probes Supermix (Bio-Rad).
Antibodies included the following: mouse monoclonal (L34F12) anti-p44/ p42 (Cell Signal; catalog #4696; 1:2,000); rabbit monoclonal (D13.14.4E) antiphospho-p44/p42 (Cell Signal; catalog #4370; 1:2,000); mouse anti-TBP (Abcam; catalog #ab818; 1:1,000); rabbit anti-β-Tubulin (Abcam; catalog #ab6046; 1:1,000); rabbit polyclonal anti-Brf1/2 (Cell Signal; catalog #2119; 1:1,000); rabbit anti-Zfp36 (Protein Tech Group; catalog #12737-1-AP; 1:500); rabbit anti-hnRNP E1 (Cell Signal; catalog #8534; 1:500); goat anti-Brachyury (R&D Systems; catalog #AF2085; 1:200); rabbit anti-Sox1 (GeneTex; catalog #GTX62974; 1:200); mouse anti-Gapdh (Abcam; catalog #ab8245; 1:5,000).
Signaling inhibitors included the following: CI-1040 (also known as PD184352; Axon; 5 μM); PD173074 (Sigma; 100 ng/mL). siRNAs included the following: TTP siRNA (Santa Cruz Biotechnology; 10 nM); Brf1 siRNA (Santa Cruz Biotechnology; 10 nM); Brf2 siRNA (Santa Cruz Biotechnology; 10 nM); All Stars Negative Control siRNA (Qiagen; 10 nM).
Measurement of mRNA Half-Life. mESC cultures were cotransfected with a reverse Tet (rTet) expression plasmid (PGK-H2B-mCherry/T2A/rTet) and either CMV(2xTetO)-H2B-YFP or CMV(2xTetO)-Nanog with and without ARE site mutations at 19:1 ratio by mass. Culture media was then transitioned to media containing FGF4 and heparin (10 ng/mL and 10 μg/mL, respectively) or PBS to determine the regulatory effect of ERK MAP kinase signaling in fgf4 −/− cells. To stop transcription from the CMV-TO promoter, doxycycline was added to a concentration of 1 μg/mL to permit binding of rTet to TetO sequences. Changes in the abundance of H2B-YFP or Nanog mRNA relative to Gapdh, Sdha, and Tbp housekeeping genes was measured using RT-qPCR. To distinguish from endogenous Nanog mRNA, we developed a primer set that specifically recognizes the 5′-UTR of Nanog expressed from the CMV(2×TetO) promoter.
Isolation of RBPs from Crude Cytoplasmic Lysates. IL-2 and Nanog RNAs were produced in vitro using T7 Ampliscribe (Epicentre Technologies). These RNAs were then hybridized to biotin-DNA oligonucleotides at their 3′ end. Two hundred picomoles of IL-2 or Nanog RNA were used for 250 pmol of biotin-DNA oligonucleotide. Hybridization reactions were added to 1 mg of streptavidin magnetic agarose beads (New England Biolabs). Crude cytoplasmic extracts used for protein pull-down assays were obtained using NE-PER reagents (Thermo Scientific). RNA/DNA-bead conjugates were incubated in crude cytoplasmic extract for 1 h at 4°C, washed five times with Binding Buffer (20 mM Tris·HCl, pH 7.5, 50 mM KCl, 1 mM EDTA, 1 mM DTT, 0.5% Triton X-100 with RNase inhibitors) and incubated in High Salt Elution Buffer (Binding Buffer plus 1 M NaCl) to collect RNA-bound protein fractions. Protein pull downs were analyzed via Western blot.
Preparation of Cells for Flow Cytometry. Cultures were harvested with 0.25% trypsin-EDTA, dispersed into a cell suspension, and added to an equal volume of 4% formaldehyde. Cells were fixed for 5 min, quenched, and gently pelleted at 500 × g for 30 s. Supernatants were removed and cell pellets were resuspended in 2.5 mg/mL BSA in 1× HBSS. The resulting cell suspensions were incubated overnight at 4°C before flow cytometry analysis. For antibody-stained cell suspensions, cell pellets containing fixed cells were resuspended in 10% FBS in PBS to block, gently pelleted, and stained with appropriate primary and secondary antibodies at 4°C. Before flow cytometry analysis, cells were pelleted and resuspended in 2.5 mg/mL BSA in 1× HBSS. All samples, stained and unstained, were analyzed with a Miltenyi Biotec VYB flow cytometer. Compensation and background correction were applied postacquisition.
RNA/RBP Immunoprecipitation and RNA Sequencing. RBP-mRNA complexes were isolated using a Magna-RIP kit (Millipore). Briefly, cytoplasmic extract from ∼1 × 10 7 E14 mESCs was distributed equally among two samples and two controls. For sample reactions, 5 μg of α-Brf1/2 antibody was used for 50 μL of magnetic protein A/G beads. For control reactions, 5 μg of rabbit IgG with no immunoreactivity was used for 50 μL of magnetic protein A/G beads. After stringency washes and proteinase K digestion, RNA was isolated using Qiazol reagent.
RNA/RBP immunoprecipitation (RIP)-purified RNAs and total RNA from E14 mESCs were prepared for sequencing using a TruSeq RNA Sample Prep kit. RNAs were fragmented to generate lengths of ∼200 nt, reverse transcribed with random hexameric primers to generate double-stranded DNA, blunted, adenylated, and ligated to Illumina sequencing adapters (150 bp). DNA fragments were gel separated, and all fragments running at 350 bp were extracted and amplified. Amplified DNA fragments were then sequenced using an Illumina HiSeq2000.
RNA-Sequencing Analysis Tools and Methods. Raw sequencing reads were trimmed (of 13 nt from 5′ end) before Bowtie mapping using a mouse transcript annotation containing only protein coding genes (18,313 genes), derived from NCBI37/mm9 genome build. Mapping statistics were generated using eXpress (46) . For enrichment analysis, fragments per kilobase exon per million mapped reads (FPKM) were used as a measure of transcript abundance (47) .
We computed a statistic (E RIP,n ) that represents the degree to which the abundance of the nth transcript is enriched by antibody-mediated RIP. This statistic uses differences in a transcript's abundance after Brf1/2 antibody RIP (mean FPKM BRF,n ) compared with rabbit IgG RIP (mean FPKM IgG,n ), normalized by their initial abundance in total RNA before RIP (mean FPKM Total,n ). This difference was further normalized by a penalty factor (P), which accounts for a transcript's tendency to be nonspecifically purified, and is thus a saturating function of transcript abundance in the IgG control experiment: E RIP,n = À A BRF,n − A IgG,n Á P , where A BRF,n = mean FPKM BRF,n mean FPKM Total,n , A IgG,n = mean FPKM IgG,n mean FPKM Total,n , P = median À A IgG Á + A IgG,n :
Although A IgG,n captures the level of nonspecific association of a transcript with assay components (i.e., protein A/G beads, rabbit IgG, etc.), nonspecific association of transcripts with immunoprecipitated RBP/RNA complexes could not be independently quantified, and could contribute a background to these E RIP,n values.
High-Throughput Sequencing Data. Raw sequencing data discussed in this publication were deposited in the National Center for Biotechnology Information Gene Expression Omnibus database (accession no. GSE40104).
